Regeneron (NASDAQ:REGN) is today's big loser in the biotech space because of a new set of FDA concerns over its PCSK9 drug. The FDA is now concerned that this class of drugs, aimed at lowering "bad" cholesterol in the bloodstream, could have a number of neurocognitive adverse effects in patients. Amgen (NASDAQ:AMGN) has a drug in this class, as well, that is considered a critical product for the company; it also saw shares fall today.

In this video from Friday's Market Checkup, Motley Fool health-care analyst David Williamson discusses this potentially multi-billion dollar blockbuster drug class, and how likely these FDA concerns are to derail these drugs.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.